Trial Profile

A Phase-2, Open-Label Study of Oral Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary)
Indications Prostate cancer
Focus Therapeutic Use
Acronyms SHIP
Sponsors Karyopharm Therapeutics

Most Recent Events

23 Mar 2016 Status changed from recruiting to discontinued due to enrollment challenges as reported by ClinicalTrials.gov.
22 Feb 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017, according to ClinicalTrials.gov record.
22 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com